{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=7", "query": { "condition": "Gastrointestinal Cancer Metastatic", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 2359, "total_pages": 236, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:16:17.106Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05277051", "title": "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Remzistotug", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Belrestotug", "type": "DRUG" }, { "name": "Nelistotug", "type": "DRUG" }, { "name": "GSK5764227", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2022-03-22", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 7, "location_summary": "San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05277051" }, { "nct_id": "NCT07909031", "title": "CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)", "Gastric/GEJ", "Biliary Tract Cancer (BTC)", "Esophageal Squamous Cell Carcinoma (ESCC)", "Ovarian Cancer", "Endometrial Cancer", "Cervical Cancer Metastatic", "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "CR-002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crescent Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2026-10-21", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 3, "location_summary": "Austin, Texas • Dallas, Texas • Fairfax, Virginia", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07909031" }, { "nct_id": "NCT00690677", "title": "Phase II Trial of LBH589 in Refractory Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "LBH589", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Swedish Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2008-06", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-01-18", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00690677" }, { "nct_id": "NCT02581501", "title": "Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "GAX - Gemcitabine, Abraxane and Xeloda", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stamford Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-02", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 1, "location_summary": "Stamford, Connecticut", "locations": [ { "city": "Stamford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02581501" }, { "nct_id": "NCT01754272", "title": "A Non-Interventional Follow-Up to the VELOUR Study - Translational Research", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "KU Leuven", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1226, "start_date": "2012-01", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2012-12-21", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01754272" }, { "nct_id": "NCT04543071", "title": "Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Adenocarcinoma of the Pancreas", "Adenocarcinoma" ], "interventions": [ { "name": "Motixafortide", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2020-11-09", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Providence, Rhode Island + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04543071" }, { "nct_id": "NCT02062632", "title": "Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Carcinoma", "Hypopharyngeal Carcinoma", "Laryngeal Carcinoma", "Lymphoma", "Mesothelioma", "Metastatic Malignant Neoplasm in the Lung", "Metastatic Malignant Neoplasm in the Pleura", "Metastatic Malignant Neoplasm in the Spinal Cord", "Non-Small Cell Lung Carcinoma", "Sarcoma", "Small Cell Lung Carcinoma", "Thymic Carcinoma", "Thymoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Doxepin Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-04-14", "completion_date": "2017-11-06", "has_results": true, "last_update_posted_date": "2019-10-01", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 3, "location_summary": "Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Green Bay", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02062632" }, { "nct_id": "NCT02703571", "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors for Phase Ib", "Pancreatic Cancer for Phase II", "Colorectal Cancer for Phase II" ], "interventions": [ { "name": "ribociclib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2016-06-29", "completion_date": "2019-09-24", "has_results": false, "last_update_posted_date": "2020-12-21", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 6, "location_summary": "Fayetteville, Arkansas • Duarte, California • New Haven, Connecticut + 3 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02703571" }, { "nct_id": "NCT04148937", "title": "A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "LY3475070", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2020-01-16", "completion_date": "2022-06-20", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 7, "location_summary": "Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04148937" }, { "nct_id": "NCT02127359", "title": "Whole-Exome Sequencing (WES) of Cancer Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Adenocarcinoma", "Colon Adenocarcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2012-09", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2021-02-10", "last_synced_at": "2026-11-15T12:16:17.106Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02127359" } ] }